Healthy Volunteers
Conditions
Brief summary
Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare the Pharmacokinetics (PK), safety and immunogenicity profile of MB02 with US and EU Avastin® in healthy male subjects. During the course of the study, the similarity in pharmacokinetics will be assessed by sampling the levels of drug in the blood, and by comparing these levels among the different administration arms. Safety, tolerability, and immunologic response to the administered drugs will also be evaluated throughout.
Detailed description
The primary PK parameters are Cmax and AUC(0-∞). The PK parameters for bevacizumab will be calculated using standard noncompartmental methods. An analysis of covariance model will be used to analyse the log-transformed primary PK parameters (AUC\[0-∞\].and Cmax) and AUC(0-t). The model will include a fixed effect for treatment and body weight as a covariate. All other PK parameters will not be subject to inferential statistical analysis. Estimates of geometric mean ratios together with the corresponding 90% confidence intervals will be derived for the comparisons of the PK parameters as follows: * MB02 versus EU Avastin® * MB02 versus US Avastin® * EU Avastin® versus US Avastin® PK similarity will be achieved if the 90% confidence intervals (CIs) for the biosimilar-to-reference ratios of PK endpoints (AUC\[0-∞\] and Cmax) fall within the predefined 0.80-1.25 acceptance similarity criteria for all 3 pairwise comparisons; MB02 versus EU-approved Avastin®; MB02 versus US-licenced Avastin®; and EU-approved Avastin® versus US-licenced Avastin®. All AEs will be listed and summarised using descriptive methodology. All observed or patient-reported AEs will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. The incidence of AEs for each treatment will be presented by severity and by association with the study drugs as determined by the Investigator (or designee). All safety data will be listed and summarised as appropriate Immunogenicity data (overall anti-drug antibody \[ADA\] incidence and titers, and neutralising ADA results) will be listed. A summary of the number and percent of subjects testing positive for ADA or neutralising antibodies before the dose of MB02, EU Avastin®, or US Avastin® (Day 1) and at scheduled postdose assessments will be presented by treatment arm.
Interventions
DRUGMB02
Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
Sponsors
mAbxience Research S.L.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Males of any race, between 18 and 55 years of age, inclusive, at Screening. 2. Body mass index between 18.5 and 29.9 kg/m2, inclusive, at Screening. 3. Total body weight between 60 and 95 kg, inclusive, at Screening. 4. In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations (congenital nonhaemolytic hyperbilirubinemia \[eg, Gilbert's syndrome\] is acceptable) at Screening or Check-in as assessed by the Investigator (or designee). 5. Relevant clinical laboratory evaluations of haematology, coagulation, urinalysis and clinical chemistry within normal range at Screening and Check in as follows. A single repeat test will be allowed at each timepoint. * Absolute neutrophil count ≥1.5 × 109 L * Platelet count ≥100 × 109 L * Haemoglobin \>10 g/dl * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ ULN * Alkaline phosphatase (ALP) ≤1.5 × ULN * Total bilirubin \<1.5 × ULN (\<51.30 µmol/L in subjects with Gilbert's syndrome) * Blood urea nitrogen ≤1.5 × ULN * Creatinine \< 132.63 µmol/L * Serum albumin: \>35 g/L * Low density lipoprotein cholesterol ≤ ULN * High density lipoprotein cholesterol ≥ lower limit of normal * Creatine kinase (CK) \< × 2 ULN * International normalised ratio (INR) 0.8-1.3 * Urine dipstick for proteinuria \<2+ 6. Systolic blood pressure ≥90 mmHg and ≤140 mmHg and diastolic blood pressure ≥50 mmHg and ≤90 mmHg at Screening and Check in. 7. Subjects agree to use contraception as detailed in protocol. 8. Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions. Subjects must have signed an informed consent before any study-related procedure or evaluation is performed.
Exclusion criteria
1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee). 2. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee). 3. Any current or recent history of active infections, including localised infections. 4. History of, or planned surgery, including suturing, dental surgery or wound dehiscence within 30 days of dosing, or within 30 days of the last study visit. 5. Presence of a nonhealing wound or fracture. 6. Known history of clinically significant essential hypertension, orthostatic hypotension, fainting spells or blackouts for any reason, cardiac failure or history of thromboembolic conditions. 7. Medically significant dental disease or dental neglect, with signs and/or symptoms of local or systemic infection that would likely require a dental procedure during the course of the study. 8. Clinically relevant history of alcoholism, addiction or drug/chemical abuse prior to Check-in, and/or positive alcohol breath test and/or urinary drug test screen at Screening or Check in. 9. History of bleeding disorders or protein C, protein S, and/or factor V Leiden deficiency. 10. History of clinically signifiant haemorrhage, epistaxis, GI bleeding, haemorrhoids and/or haemoptysis. 11. History of GI perforation, ulcers, gastro oesophageal reflux, inflammatory bowel disease, diverticular disease, or any fistulae. 12. Alcohol consumption of \>24 units per week. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits. 13. Positive hepatitis panel, positive human immunodeficiency test. Subjects whose results are compatible with prior immunisation and not infection may be included at the discretion of the Investigator. 14. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days prior to Check-in, or within 5 half lives of the investigational drug used in the study. 15. Use or intend to use slow-release medications/products considered to still be active within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee). 16. Use or intend use of any prescription medications/ nonprescription products known to alter drug absorption, metabolism, or elimination processes, including St. John's Wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator or designee. 17. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee). 18. Have received a live or attenuated vaccine from 3 months prior to Screening, or have the intention to receive a vaccine during the study. 19. Intend to travel to a region where a vaccination will be required due to endemic disease within 3 months of dosing. 20. Previous treatment with an anti VEGF antibody or any other protein or antibody targeting the VEGF receptor. 21. Use of tobacco- or nicotine-containing products within 5 years prior to Check-in, or positive cotinine test upon Screening or Check-in. 22. Receipt of blood products within 60 days prior to Check-in. 23. Donation of blood from 90 days prior to Screening, plasma from 14 days prior to Screening, or platelets from 42 days prior to Screening. 24. Poor peripheral venous access. 25. History of abnormal peripheral sensation including paraesthesia and/or numbness in arms and/or legs. 26. Have previously completed or withdrawn from this study or any other study investigating bevacizumab, and/or have previously received bevacizumab. 27. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity | Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of AUC\[0-∞\]) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric least square means (GLSM) ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25. |
| Cmax: Maximum Observed Serum Concentration | Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of Cmax) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric LS means ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC(0-t) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration; | Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | To evaluate the AUC\[0-t\] of MB02, US Avastin® and EU Avastin®. |
| CL: Total Body Drug Clearance After IV Administration | Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | To evaluate the CL of MB02, US Avastin® and EU Avastin® |
| Tmax: Time of Maximum Observed Serum Concentration | Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | To evaluate the tmax of MB02, US Avastin® and EU Avastin® . |
| t1/2: Apparent Serum Terminal Elimination Half-life | Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | To evaluate the t1/2 of MB02, US Avastin® and EU Avastin® |
| Immunogenicity | Day -1, Day 14, 28, 56, and 78 | Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here. |
| Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | Day 1 - Day 100 | Compare the incidence of TEAEs reported in each treatment arm. |
Other
| Measure | Time frame | Description |
|---|---|---|
| AUC(0-∞) Adjusted: Protein-adjusted Area Under the Serum Concentration-time Curve From Time Zero to Infinity | Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as AUC is a dose-dependent PK parameter), protein-adjusted AUC(0-∞) was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax. |
| AUC(0-t) Adjusted: Protein Adjusted Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration | Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as AUC is a dose-dependent PK parameters), protein-adjusted AUC(0-t) was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax. |
| Cmax Adjusted: Protein Adjusted Maximum Observed Serum Concentration | Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as Cmax is a dose-dependent PK parameters), protein-adjusted Cmax was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax. |
Countries
United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| MB02 (Bevacizumab Biosimilar) Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
MB02: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion. | 38 |
| US Licenced Avastin® Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
US licenced Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion. | 38 |
| EU Approved Avastin® Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion. | 38 |
| Total | 114 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 38 Participants | 38 Participants | 38 Participants | 114 Participants |
| Age, Continuous | 36 years STANDARD_DEVIATION 10.8 | 35 years STANDARD_DEVIATION 9.1 | 38 years STANDARD_DEVIATION 9.9 | 37 years STANDARD_DEVIATION 9.9 |
| BMI | 24.3 kg/m^2 STANDARD_DEVIATION 2.66 | 24.3 kg/m^2 STANDARD_DEVIATION 2.61 | 25.0 kg/m^2 STANDARD_DEVIATION 2.07 | 24.5 kg/m^2 STANDARD_DEVIATION 2.46 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 5 Participants | 2 Participants | 7 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 2 Participants | 4 Participants | 9 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 1 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 35 Participants | 30 Participants | 30 Participants | 95 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 38 Participants | 38 Participants | 38 Participants | 114 Participants |
| Weight | 76.9 kg STANDARD_DEVIATION 9.38 | 77.9 kg STANDARD_DEVIATION 8.11 | 77.8 kg STANDARD_DEVIATION 8.29 | 77.6 kg STANDARD_DEVIATION 8.55 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 38 | 0 / 38 | 0 / 38 |
| other Total, other adverse events | 24 / 38 | 28 / 38 | 25 / 38 |
| serious Total, serious adverse events | 0 / 38 | 1 / 38 | 0 / 38 |
Outcome results
Primary
AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity
To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of AUC\[0-∞\]) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric least square means (GLSM) ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Population: Overall number of participants analyzed equals to number of subjects who contributed to summary statistics.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity | 28200000 ng*h/mL | Geometric Coefficient of Variation 16.3 |
| US Licenced Avastin® | AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity | 22900000 ng*h/mL | Geometric Coefficient of Variation 17.8 |
| EU Approved Avastin® | AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity | 24500000 ng*h/mL | Geometric Coefficient of Variation 15.2 |
90% CI: [1.09, 1.22]
90% CI: [1.09, 1.22]
90% CI: [1, 1.13]
Primary
Cmax: Maximum Observed Serum Concentration
To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of Cmax) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric LS means ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Population: Overall number of participants analyzed equals to number of subjects who contributed to summary statistics.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | Cmax: Maximum Observed Serum Concentration | 83000 (ng/mL)/(mg/mL) | Geometric Coefficient of Variation 22.4 |
| US Licenced Avastin® | Cmax: Maximum Observed Serum Concentration | 65200 (ng/mL)/(mg/mL) | Geometric Coefficient of Variation 21.9 |
| EU Approved Avastin® | Cmax: Maximum Observed Serum Concentration | 74400 (ng/mL)/(mg/mL) | Geometric Coefficient of Variation 25.3 |
90% CI: [1.18, 1.39]
90% CI: [1.03, 1.22]
90% CI: [1.05, 1.24]
Secondary
AUC(0-t) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration;
To evaluate the AUC\[0-t\] of MB02, US Avastin® and EU Avastin®.
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | AUC(0-t) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration; | 27400000 ng*h/mL | Geometric Coefficient of Variation 15.5 |
| US Licenced Avastin® | AUC(0-t) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration; | 22300000 ng*h/mL | Geometric Coefficient of Variation 16.9 |
| EU Approved Avastin® | AUC(0-t) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration; | 23700000 ng*h/mL | Geometric Coefficient of Variation 14.2 |
Secondary
CL: Total Body Drug Clearance After IV Administration
To evaluate the CL of MB02, US Avastin® and EU Avastin®
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | CL: Total Body Drug Clearance After IV Administration | 0.00814 l/h | Geometric Coefficient of Variation 16.5 |
| US Licenced Avastin® | CL: Total Body Drug Clearance After IV Administration | 0.0101 l/h | Geometric Coefficient of Variation 17.9 |
| EU Approved Avastin® | CL: Total Body Drug Clearance After IV Administration | 0.00947 l/h | Geometric Coefficient of Variation 15.4 |
Secondary
Immunogenicity
Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here.
Time frame: Day -1, Day 14, 28, 56, and 78
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | Immunogenicity | nAb positive | 1 Participants |
| MB02 (Bevacizumab Biosimilar) | Immunogenicity | ADA positive | 2 Participants |
| MB02 (Bevacizumab Biosimilar) | Immunogenicity | NO seroconversion | 35 Participants |
| US Licenced Avastin® | Immunogenicity | nAb positive | 0 Participants |
| US Licenced Avastin® | Immunogenicity | ADA positive | 2 Participants |
| US Licenced Avastin® | Immunogenicity | NO seroconversion | 36 Participants |
| EU Approved Avastin® | Immunogenicity | ADA positive | 1 Participants |
| EU Approved Avastin® | Immunogenicity | NO seroconversion | 37 Participants |
| EU Approved Avastin® | Immunogenicity | nAb positive | 0 Participants |
Secondary
Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03)
Compare the incidence of TEAEs reported in each treatment arm.
Time frame: Day 1 - Day 100
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | Subjects with TEAEs | 24 participants |
| MB02 (Bevacizumab Biosimilar) | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | TEAEs of mild severity | 24 participants |
| MB02 (Bevacizumab Biosimilar) | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | Related TEAEs | 6 participants |
| MB02 (Bevacizumab Biosimilar) | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | Subjects with SAEs | 0 participants |
| MB02 (Bevacizumab Biosimilar) | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | TEAEs of severe severity | 0 participants |
| MB02 (Bevacizumab Biosimilar) | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | TEAEs of moderate severity | 4 participants |
| MB02 (Bevacizumab Biosimilar) | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | Subjects discontinued due to TEAEs | 0 participants |
| US Licenced Avastin® | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | Subjects with TEAEs | 28 participants |
| US Licenced Avastin® | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | Subjects with SAEs | 1 participants |
| US Licenced Avastin® | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | Subjects discontinued due to TEAEs | 0 participants |
| US Licenced Avastin® | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | Related TEAEs | 3 participants |
| US Licenced Avastin® | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | TEAEs of mild severity | 25 participants |
| US Licenced Avastin® | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | TEAEs of moderate severity | 10 participants |
| US Licenced Avastin® | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | TEAEs of severe severity | 1 participants |
| EU Approved Avastin® | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | TEAEs of mild severity | 24 participants |
| EU Approved Avastin® | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | Subjects with SAEs | 0 participants |
| EU Approved Avastin® | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | TEAEs of severe severity | 0 participants |
| EU Approved Avastin® | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | TEAEs of moderate severity | 5 participants |
| EU Approved Avastin® | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | Related TEAEs | 8 participants |
| EU Approved Avastin® | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | Subjects discontinued due to TEAEs | 0 participants |
| EU Approved Avastin® | Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03) | Subjects with TEAEs | 25 participants |
Secondary
t1/2: Apparent Serum Terminal Elimination Half-life
To evaluate the t1/2 of MB02, US Avastin® and EU Avastin®
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | t1/2: Apparent Serum Terminal Elimination Half-life | 451 h | Geometric Coefficient of Variation 14.4 |
| US Licenced Avastin® | t1/2: Apparent Serum Terminal Elimination Half-life | 437 h | Geometric Coefficient of Variation 15.5 |
| EU Approved Avastin® | t1/2: Apparent Serum Terminal Elimination Half-life | 449 h | Geometric Coefficient of Variation 19.3 |
Secondary
Tmax: Time of Maximum Observed Serum Concentration
To evaluate the tmax of MB02, US Avastin® and EU Avastin® .
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| MB02 (Bevacizumab Biosimilar) | Tmax: Time of Maximum Observed Serum Concentration | 2.51 h |
| US Licenced Avastin® | Tmax: Time of Maximum Observed Serum Concentration | 4.00 h |
| EU Approved Avastin® | Tmax: Time of Maximum Observed Serum Concentration | 3.00 h |
Other Pre-specified
AUC(0-∞) Adjusted: Protein-adjusted Area Under the Serum Concentration-time Curve From Time Zero to Infinity
Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as AUC is a dose-dependent PK parameter), protein-adjusted AUC(0-∞) was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | AUC(0-∞) Adjusted: Protein-adjusted Area Under the Serum Concentration-time Curve From Time Zero to Infinity | 1040000 ng*h/mL | Geometric Coefficient of Variation 16.3 |
| US Licenced Avastin® | AUC(0-∞) Adjusted: Protein-adjusted Area Under the Serum Concentration-time Curve From Time Zero to Infinity | 981000 ng*h/mL | Geometric Coefficient of Variation 18.1 |
| EU Approved Avastin® | AUC(0-∞) Adjusted: Protein-adjusted Area Under the Serum Concentration-time Curve From Time Zero to Infinity | 1020000 ng*h/mL | Geometric Coefficient of Variation 14.5 |
90% CI: [0.962, 1.07]
90% CI: [0.996, 1.13]
90% CI: [0.983, 1.11]
Other Pre-specified
AUC(0-t) Adjusted: Protein Adjusted Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration
Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as AUC is a dose-dependent PK parameters), protein-adjusted AUC(0-t) was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | AUC(0-t) Adjusted: Protein Adjusted Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration | 1010000 ng*h/mL | Geometric Coefficient of Variation 15.5 |
| US Licenced Avastin® | AUC(0-t) Adjusted: Protein Adjusted Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration | 955000 ng*h/mL | Geometric Coefficient of Variation 17.2 |
| EU Approved Avastin® | AUC(0-t) Adjusted: Protein Adjusted Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration | 991000 ng*h/mL | Geometric Coefficient of Variation 13.6 |
90% CI: [0.998, 1.12]
90% CI: [0.981, 1.1]
90% CI: [0.969, 1.07]
Other Pre-specified
Cmax Adjusted: Protein Adjusted Maximum Observed Serum Concentration
Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as Cmax is a dose-dependent PK parameters), protein-adjusted Cmax was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | Cmax Adjusted: Protein Adjusted Maximum Observed Serum Concentration | 3050 (ng/mL)/(mg/mL) | Geometric Coefficient of Variation 22.4 |
| US Licenced Avastin® | Cmax Adjusted: Protein Adjusted Maximum Observed Serum Concentration | 2790 (ng/mL)/(mg/mL) | Geometric Coefficient of Variation 22.1 |
| EU Approved Avastin® | Cmax Adjusted: Protein Adjusted Maximum Observed Serum Concentration | 3110 (ng/mL)/(mg/mL) | Geometric Coefficient of Variation 25.2 |
90% CI: [1.02, 1.22]
90% CI: [0.903, 1.08]
90% CI: [1.01, 1.19]